Dr. Kathleen Moore is currently a Professor in the Division of Gynecologic Oncology at the University of Oklahoma. She is the Associate Director for Clinical Research and the Director of the Phase I Drug Development Unit at the Stephenson Cancer Center at the University of Oklahoma. She also serves as the medical director for infusion services and is a recent director of the gynecologic oncology fellowship. She received her MD from the University of Washington School of Medicine in 2000 with high honors. She completed her residency in Obstetrics and Gynecology at Magee Womens Hospital, Pittsburgh, PA in 2004 and went on to complete her fellowship in Gynecologic Oncology at the University of Oklahoma in 2007. She has been on faculty at the University of Oklahoma since 2007. Nationally she serves as the NRG Chair for Ovarian Cancer, Associate Director for GOG-Partners and serves on the GOG Foundation Board of Directors. Her interests include drug development and clinical trialist mentorship in gynecologic cancers. She has served as PI for phase I, II and III trials including several with registration intent. These include the randomized phase 3 study of olaparib maintenance following response to front line platinum based chemotherapy in patients with BRCAmut ovarian cancer (SOLO-1), the randomized phase 3 trial of mirvetuximab for treatment of platinum resistant, FRα high ovarian cancer (MIRASOL) and the randomized phase 3 trial of atezolizumab incorporated into front line, bevaciziumab containing platinum based therapy for ovarian cancer (IMagyn050). She has authored over 400 manuscripts, speaks nationally and internationally about gynecologic cancers and has authored many book chapters and educational content. She lives in Oklahoma with her husband Jeff, 7 dogs, 1 cat and many fish.